Entities / Company
Innovent Biologics.
Chinese Biopharmaceutical Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 16
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Some support2 reports
-
FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.Some support2 reports2 developments inside
-
Innovent Biologics commercializes mazdutide for OPKO's license.Some support2 reports
One to three months ago
-
Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.Some support2 reports
-
Innovent Biologics, a company based in China, focuses on global markets.Some support1 report
-
Innovent Biologics and Definium Therapeutics, Inc. are biopharmaceutical companies currently competing for investment.Some support1 report
-
Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.Some support2 reports1 development inside
-
HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Innovent Biologics this week
News at the entities that move Innovent Biologics most-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Innovent Biologics
-
Pfizer TransactionalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Innovent Biologics
-
Daiichi Sankyo StructuralThe Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Moves Innovent Biologics
-
Akeso OperationalJanus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Moves Innovent Biologics
Connections
The 4 strongest of 16, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Pfizer Transactional
Innovent Biologics and Pfizer entered a major partnership worth up to $10.5 billion, impacting financial guidance.
-
Eli Lilly and Company Operational
Innovent Biologics functions as a dedicated marketing and distribution partner for Eli Lilly and Company in the Chinese market.
-
Daiichi Sankyo Structural
Exclusive agreement for the commercialization and supply of Vanflyta.
-
Akeso Operational
Both companies are identified as key players and competitors within the Chinese biopharma sector.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
4 events- Innovent Biologics, a company based in China, focuses on global markets.
- Innovent Biologics and Definium Therapeutics, Inc. are biopharmaceutical companies currently competing for investment.
- Innovent Biologics partnered with Spero Therapeutics Inc. to advance the development of IBI355.
- HCRx buys into Utebzi milestones and royalties, GSK grants exclusive license for Utebzi, and Spero in-licenses SP001 from Innovent Biologics.
Show 1 earlier month
June 2026
3 events- Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- Ollin Biosciences is developing compounds (OLN102, OLN324) that target and challenge the market share of Amgen's Tepezza and Vabysmo.